NASDAQ:TGTX TG Therapeutics Q3 2026 Earnings Report $52.04 -1.87 (-3.47%) As of 12:29 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast TG Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.36Beat/MissN/AOne Year Ago EPSN/ATG Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$245.18 millionBeat/MissN/AYoY Revenue GrowthN/ATG Therapeutics Announcement DetailsQuarterQ3 2026Date11/2/2026TimeBefore Market OpensConference Call DateMonday, November 2, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile TG Therapeutics Earnings HeadlinesTG Therapeutics (NASDAQ:TGTX) Stock Breaks Above 200-Day Moving Average - Here's What HappenedOctober 6 at 3:21 AM | americanbankingnews.comKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmSeptember 28, 2026 | prnewswire.comWhy The Biggest Names in AI Are Heading To The ArcticGoogle contracted over 12 GW of energy last year and just announced a 15 billion dollar AI infrastructure investment in Finland. Cerebras followed with plans for a 165 MW data center worth up to 1.7 billion euros. One small Nasdaq-listed company built its Nordic footprint before this wave hit, with up to 190 MW of capacity approaching ready-for-service status in 2027 to early 2028. Recent long-term data center deals have valued capacity at 1.7 to 2 million dollars per MW annually. See why this overlooked company could be next in the AI infrastructure spotlight.October 6 at 1:00 AM | The Tomorrow Investor (Ad)TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Average Target Price of $63.00September 27, 2026 | americanbankingnews.comHead-To-Head Comparison: Puma Biotechnology (NASDAQ:PBYI) & TG Therapeutics (NASDAQ:TGTX)September 26, 2026 | americanbankingnews.comTG Therapeutics Inc (TGTX)September 24, 2026 | ru.investing.comSee More TG Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TG Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TG Therapeutics and other key companies, straight to your email. Email Address About TG TherapeuticsTG Therapeutics (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways. TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. BRIUMVI is administered by intravenous infusion and is intended to reduce disease activity and delay disability progression. The company commercializes BRIUMVI in the United States and continues to evaluate opportunities to expand its use in additional immune-mediated conditions. TG Therapeutics is led by Michael S. Weiss, who serves as chairman and chief executive officer. The company has historically focused its development efforts on therapies for B-cell malignancies and autoimmune diseases.View TG Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
